Compare Google Inc (GOOG) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Google Inc vs Sana Biotechnology Inc — how do they compare? Google Inc trades at $358.74 (market cap $4.52T), while Sana Biotechnology Inc trades at $3.23 (market cap $987.94M). The key difference: Google Inc is far larger — about 4575.2× Sana Biotechnology Inc's market cap, and Google Inc pays a 0.24% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| GOOG | SANA | |
|---|---|---|
Market Cap | $4.52T | $987.94M |
Volume | 1,511,127 | — |
Sector | Technology | Health |
52-Week High | $399.06 | $5.92 |
52-Week Low | $183.77 | $2.68 |
Enterprise Value | $4.49T | $962.13M |
Dividend Yield | 0.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOG) trades at $370.43, up 3.67% on the day, with strong bullish momentum from recent earnings beats and a consensus analyst price target of $457.50. The stock shows robust fundamentals with 2025 revenue of $402.84B, net income margin of 37.92%, and consistent cash flow growth. Technical indicators are bullish, with the current price near resistance at $374, while sentiment is positive due to Warren Buffett's recent endorsement and AI-driven growth prospects.
Outlook remains favorable with earnings growth and AI expansion as key catalysts, though regulatory risks and market volatility pose challenges. The stock offers upside potential aligned with analyst targets, supported by high institutional ownership and strong profitability metrics.
Sana Biotechnology (SANA) trades at $3.225, down 9.66% on the day, reflecting market volatility despite a bullish technical signal and strong analyst support. The company shows significant financial losses with a -$244.17M net income for 2025 and negative cash flows, but has beaten earnings expectations in two of the last three quarters. Recent news highlights clinical progress in cell therapies and a $69M capital raise via an ATM facility in May 2026.
The investment case balances high-risk fundamentals against promising clinical developments and overwhelming analyst optimism. While substantial losses and cash burn present clear risks, the company's scientific advancements and 82% buy rating from analysts suggest potential long-term upside for risk-tolerant investors in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
